Nadja West Sells 3,000 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director Nadja West sold 3,000 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $69.00, for a total transaction of $207,000.00. Following the completion of the sale, the director directly owned 31,981 shares in the company, valued at approximately $2,206,689. The trade was a 8.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Trading Down 0.5%

Tempus AI stock opened at $61.94 on Thursday. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $104.32. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The stock has a market capitalization of $11.18 billion, a P/E ratio of -43.01 and a beta of 3.71. The stock has a 50-day simple moving average of $55.41 and a 200 day simple moving average of $51.95.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business’s revenue was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.22) earnings per share. Analysts expect that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on TEM. Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Cantor Fitzgerald began coverage on shares of Tempus AI in a research report on Wednesday. They issued an “overweight” rating and a $80.00 price objective on the stock. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Wolfe Research initiated coverage on shares of Tempus AI in a report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Finally, Weiss Ratings lowered shares of Tempus AI from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. Eleven analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $68.93.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEM. Pictet Asset Management Holding SA boosted its holdings in Tempus AI by 291.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after purchasing an additional 36,096 shares during the period. Eagle Health Investments LP bought a new position in shares of Tempus AI during the first quarter worth approximately $11,588,000. Alethea Capital Management LLC acquired a new stake in shares of Tempus AI in the fourth quarter valued at approximately $1,863,000. Aristotle Atlantic Partners LLC bought a new stake in shares of Tempus AI in the first quarter valued at approximately $6,179,000. Finally, Vanguard Group Inc. boosted its stake in shares of Tempus AI by 8.7% in the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after buying an additional 817,014 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Piper Sandler upgraded Tempus AI (TEM) to Overweight from Neutral and raised its price target to $76 from $56, citing growth drivers that could support further gains. Piper Sandler upgrade
• Positive Sentiment: Cantor Fitzgerald initiated coverage with an Overweight rating and an $80 price target, implying meaningful upside from recent trading levels. The firm highlighted Tempus’ data and applications segment as an important source of growth and value. Cantor Fitzgerald coverage
• Positive Sentiment: Analyst commentary argues that Tempus’ data business is being valued more like a conventional vendor than a scalable technology platform. If Tempus can demonstrate recurring, higher-margin data revenue and broader platform adoption, investors could assign it a higher valuation multiple. Tempus AI data valuation analysis
• Neutral Sentiment: The latest analyst reports improve sentiment, but the broader consensus remains Hold, with an average price target of $67.23. Tempus recently exceeded quarterly EPS and revenue estimates, while revenue increased 21.6% year over year; however, the company remains unprofitable and analysts expect a full-year loss.
• Negative Sentiment: Director Nadja West sold 3,000 shares for approximately $207,000, reducing her position by 8.58%. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which reduces its significance as a discretionary bearish signal but may still weigh modestly on sentiment. Tempus AI director share sale

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.